MADERA THERAPEUTICS

Madera Therapeutics has identified the best-in-class, chemically novel, small molecule anti-cancer agents that act through a new mechanism of action. These drugs function via an initial disruption of mitochondrial function ultimately leading to an immune response against the cancer. Lead molecules show significant biological activity on many drug resistant cancers: triple negative breast cancer, endometrial cancer, pancreatic cancer and B-cell lymphomas, addressing umet clinical needs for large patient populations. Our technology is protected by the most extensive patent portfolio in the area.